Nordic Nanovector AS: The Board appoints Mr. Luigi Costa as new CEO
The Board of Nordic Nanovector is pleased to announce the appointment of Mr. Luigi Costa as new CEO of the Company.
Mr. Costa has over 20 years of international pharmaceutical and biotech experience.
Most recently he held the position of Vice President Europe, Middle East and Africa for Onyx Pharmaceuticals, a global biopharmaceutical company based in South San Francisco, California. He was responsible for the startup of the Company’s international organization and for the pre-launch and launch of its Hematology potential blockbuster Kyprolis outside the US.
Prior to joining Onyx Pharmaceuticals, he held several roles of increasing responsibility with Amgen including Head of International Oncology Franchise, General Manager of Italy and Vice President and General Manager of France, the Company’s largest market outside the US.
Mr. Costa started his career in the pharmaceutical industry at Eli Lilly in Italy followed by 5 years at the Company’s US headquarters, where after leading the CNS Sales South Region, he headed Global Pricing and Access for the CNS portfolio.
Mr. Costa, is a highly successful senior commercial bio-pharma/'biotech' leader in Europe. He has delivered a track record across diverse products and therapeutic areas with experience gained on both sides of the Atlantic.
He holds a Bachelor’s degree in Business Administration from the University of Parma, and an MBA from SDA Bocconi in Milan. He currently resides near Zurich, Switzerland and is an active member of Help for Hope, a nonprofit organization with the mission to help children in need around the world (www.help-for-hope.com). Mr. Luigi Costa will take over as CEO on the 1st September 2014.
”We are about to enter a new and more international phase in the development of Nordic Nanovector. The Board is therefore pleased that Mr. Luigi Costa has accepted to take over the helm as CEO and take the Company to its new phase,” says Chairman Roy H. Larsen on behalf of the Board. ”We see this as yet another professional acknowledgement of the Company and its product Betalutin’s future potential.”
”We are grateful for Jan A. Alfheim’s personal commitment and contributions as CEO in building up the organization of the Company in the first years of its lifetime” says Roy H. Larsen.
Roy H. Larsen, Chairman of the Board
Phone: ( 47) 22 18 33 02
Cell: ( 47) 92 01 64 87
About Nordic Nanovector AS
Nordic Nanovector AS is a privately held company established in 2009. The company is based in Norway and has offices and laboratories in Oslo. The company is developing novel innovative anticancer radioimmunotherapeutics to treat non-Hodgkin Lymphoma (NHL) and other hematological malignancies.
Betalutin™, is a pharmaceutical product candidate consisting of a radionuclide conjugated to a tumor seeking carrier/antibody, which can be used for irradiation of malignant metastasized tumors with minimal damage to nearby healthy normal tissue. This technology aims to prolong and improve the quality of life of people who suffer from non-Hodgkin Lymphoma (NHL).